# Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF/HFmrEF)

> **NCT05328752** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 27 (actual)

## Conditions studied

- Heart Failure With Reduced Ejection Fraction (HFrEF)
- or Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)

## Interventions

- **DRUG:** XXB750
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05328752
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-17
- **Primary completion:** 2024-01-18
- **Final completion:** 2024-01-18
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05328752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05328752, "Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF/HFmrEF)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05328752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*